Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1001/jamanetworkopen.2020.37053 http://scihub22266oqcxt.onion/10.1001/jamanetworkopen.2020.37053 33566109!7876591!33566109     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 302.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 302.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 302.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       JAMA+Netw+Open 2021 ; 4 (2): e2037053 Nephropedia Template TP {{tp|p=33566109|t=2021. Association of alpha1-Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark |pdf=|usr=}}{{33566109}} gab.com Text Association of alpha1-Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark JO: JAMA Netw Open http://www.kidney.de/pget.php?&tw=1&pmid=33566109 #FOAvip IMPORTANCE: Alpha 1-adrenergic receptor blocking agents (alpha1-blockers) have been reported to have protective benefits against hyperinflammation and cytokine storm syndrome, conditions that are associated with mortality in patients with coronavirus disease 2019 and other severe respiratory tract infections. However, studies of the association of alpha1-blockers with outcomes among human participants with respiratory tract infections are scarce. OBJECTIVE: To examine the association between the receipt of alpha1-blockers and outcomes among adult patients hospitalized with influenza or pneumonia. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used data from Danish national registries to identify individuals 40 years and older who were hospitalized with influenza or pneumonia between January 1, 2005, and November 30, 2018, with follow-up through December 31, 2018. In the main analyses, patients currently receiving alpha1-blockers were compared with those not receiving alpha1-blockers (defined as patients with no prescription for an alpha1-blocker filled within 365 days before the index date) and those currently receiving 5alpha-reductase inhibitors. Propensity scores were used to address confounding factors and to compute weighted risks, absolute risk differences, and risk ratios. Data were analyzed from April 21 to December 21, 2020. EXPOSURES: Current receipt of alpha1-blockers compared with nonreceipt of alpha1-blockers and with current receipt of 5alpha-reductase inhibitors. MAIN OUTCOMES AND MEASURES: Death within 30 days of hospital admission and risk of intensive care unit (ICU) admission. RESULTS: A total of 528?467 adult patients (median age, 75.0 years; interquartile range, 64.4-83.6 years; 273?005 men [51.7%]) were hospitalized with influenza or pneumonia in Denmark between 2005 and 2018. Of those, 21?772 patients (4.1%) were currently receiving alpha1-blockers compared with a population of 22?117 patients not receiving alpha1-blockers who were weighted to the propensity score distribution of those receiving alpha1-blockers. In the propensity score-weighted analyses, patients receiving alpha1-blockers had lower 30-day mortality (15.9%) compared with patients not receiving alpha1-blockers (18.5%), with a corresponding risk difference of -2.7% (95% CI, -3.2% to -2.2%) and a risk ratio (RR) of 0.85 (95% CI, 0.83-0.88). The risk of ICU admission was 7.3% among patients receiving alpha1-blockers and 7.7% among those not receiving alpha1-blockers (risk difference, -0.4% [95% CI, -0.8% to 0%]; RR, 0.95 [95% CI, 0.90-1.00]). A comparison between 18?280 male patients currently receiving alpha1-blockers and 18?228 propensity score-weighted male patients currently receiving 5alpha-reductase inhibitors indicated that those receiving alpha1-blockers had lower 30-day mortality (risk difference, -2.0% [95% CI, -3.4% to -0.6%]; RR, 0.89 [95% CI, 0.82-0.96]) and a similar risk of ICU admission (risk difference, -0.3% [95% CI, -1.4% to 0.7%]; RR, 0.96 [95% CI, 0.83-1.10]). CONCLUSIONS AND RELEVANCE: This cohort study's findings suggest that the receipt of alpha1-blockers is associated with protective benefits among adult patients hospitalized with influenza or pneumonia. Twit Text FOAVip Association of alpha1-Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark ????JAMA Netw Open http://www.kidney.de/pget.php?&tw=1&pmid=33566109 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33566109 #FOAvip English Wikipedia <ref>{{Cite pmid|33566109}}</ref> Association of alpha1-Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark #MMPMID33566109 Thomsen RW; Christiansen CF; Heide-Jorgensen U; Vogelstein JT; Vogelstein B; Bettegowda C; Tamang S; Athey S; Sorensen HT JAMA Netw Open 2021[Feb]; 4 (2): e2037053 PMID33566109show ga IMPORTANCE: Alpha 1-adrenergic receptor blocking agents (alpha1-blockers) have been reported to have protective benefits against hyperinflammation and cytokine storm syndrome, conditions that are associated with mortality in patients with coronavirus disease 2019 and other severe respiratory tract infections. However, studies of the association of alpha1-blockers with outcomes among human participants with respiratory tract infections are scarce. OBJECTIVE: To examine the association between the receipt of alpha1-blockers and outcomes among adult patients hospitalized with influenza or pneumonia. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used data from Danish national registries to identify individuals 40 years and older who were hospitalized with influenza or pneumonia between January 1, 2005, and November 30, 2018, with follow-up through December 31, 2018. In the main analyses, patients currently receiving alpha1-blockers were compared with those not receiving alpha1-blockers (defined as patients with no prescription for an alpha1-blocker filled within 365 days before the index date) and those currently receiving 5alpha-reductase inhibitors. Propensity scores were used to address confounding factors and to compute weighted risks, absolute risk differences, and risk ratios. Data were analyzed from April 21 to December 21, 2020. EXPOSURES: Current receipt of alpha1-blockers compared with nonreceipt of alpha1-blockers and with current receipt of 5alpha-reductase inhibitors. MAIN OUTCOMES AND MEASURES: Death within 30 days of hospital admission and risk of intensive care unit (ICU) admission. RESULTS: A total of 528?467 adult patients (median age, 75.0 years; interquartile range, 64.4-83.6 years; 273?005 men [51.7%]) were hospitalized with influenza or pneumonia in Denmark between 2005 and 2018. Of those, 21?772 patients (4.1%) were currently receiving alpha1-blockers compared with a population of 22?117 patients not receiving alpha1-blockers who were weighted to the propensity score distribution of those receiving alpha1-blockers. In the propensity score-weighted analyses, patients receiving alpha1-blockers had lower 30-day mortality (15.9%) compared with patients not receiving alpha1-blockers (18.5%), with a corresponding risk difference of -2.7% (95% CI, -3.2% to -2.2%) and a risk ratio (RR) of 0.85 (95% CI, 0.83-0.88). The risk of ICU admission was 7.3% among patients receiving alpha1-blockers and 7.7% among those not receiving alpha1-blockers (risk difference, -0.4% [95% CI, -0.8% to 0%]; RR, 0.95 [95% CI, 0.90-1.00]). A comparison between 18?280 male patients currently receiving alpha1-blockers and 18?228 propensity score-weighted male patients currently receiving 5alpha-reductase inhibitors indicated that those receiving alpha1-blockers had lower 30-day mortality (risk difference, -2.0% [95% CI, -3.4% to -0.6%]; RR, 0.89 [95% CI, 0.82-0.96]) and a similar risk of ICU admission (risk difference, -0.3% [95% CI, -1.4% to 0.7%]; RR, 0.96 [95% CI, 0.83-1.10]). CONCLUSIONS AND RELEVANCE: This cohort study's findings suggest that the receipt of alpha1-blockers is associated with protective benefits among adult patients hospitalized with influenza or pneumonia. |*Hospital Mortality[MESH] |*Hospitalization[MESH] |*Intensive Care Units[MESH] |Adrenergic alpha-1 Receptor Antagonists/*therapeutic use[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/pathology[MESH] |Cohort Studies[MESH] |Denmark[MESH] |Female[MESH] |Humans[MESH] |Inflammation/*drug therapy/etiology[MESH] |Influenza, Human/*drug therapy/mortality/pathology[MESH] |Male[MESH] |Middle Aged[MESH] |Odds Ratio[MESH] |Pandemics[MESH] |Pneumonia/*drug therapy/mortality/pathology[MESH] |Propensity Score[MESH] |SARS-CoV-2[MESH]Association of alpha1-Blocker Receipt With 30-Day Mortality and Risk o(epmc).pdf DeepDyve Pubget Overpricing